Gene therapy study for high-grade bladder cancer not responding to BCG
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade bladder cancer that includes carcinoma in situ (CIS), with or without additional Ta or T1 tumors.
- Your cancer has not responded to at least two rounds of BCG treatment in the last 12 months.
- All visible papillary tumors have been surgically removed before starting the trial.
- You are not a candidate for or have chosen not to have bladder removal surgery (cystectomy).
- You are at least 18 years old and have an ECOG performance status of 0, 1, or 2 (able to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy (EG-70) given directly into the bladder for people with a high-risk bladder cancer called NMIBC. It may be an option if BCG treatment stopped working, or if you cannot have or choose not to have bladder removal surgery.
This trial tests a new drug, nadofaragene firadenovec, which uses a harmless virus to deliver a signal that helps your immune system fight low-grade cancer in the upper part of the urinary tract (the kidney area). It's given directly into the kidney through a small tube, and may avoid more invasive surgery.
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
This trial compares a gene therapy (nadofaragene firadenovec) against standard care for people with an early-stage bladder cancer that has not responded to BCG. The goal is to see if this treatment is more effective and possibly helps avoid bladder removal.
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
This trial tests a new treatment combination before bladder removal surgery for muscle-invasive bladder cancer. It uses a special virus-delivered gene therapy (nadofaragene firadenovec) plus two chemotherapy drugs (cisplatin and gemcitabine) and an immunotherapy drug (durvalumab) to try to shrink the tumor and improve outcomes.
Hear when a new Non-muscle Invasive Bladder Cancer With Carcinoma in Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.